potassium analogues, they are also markers of viability because only viable cells with intact membranes retain the tracer, reflecting the potassium space of viable tissue. In myocardial scar tissue, these potassium analogues are not taken up to the same extent as normal myocardium because of low blood flow to scar tissue associated with a corresponding fixed defect. In acutely injured myocardium these potassium analogues leak back out of necrotic cells after initial uptake, leaving an image defect reflecting loss of the potassium space and interpreted as necrosis. The kinetics of this ion leak as a measure of viability have been most clearly elucidated for 82Rb5,6 but in principle apply equally to 201T1.
FDG Versus Potassium Analogues
Which is the better measure of myocardial viability-intermediary metabolism, reflected by FDG uptake, or cell membrane integrity, reflected by uptake of 2oPfl or t2Rb? Under the right conditions and by the right protocol, the two approaches are equivalent, as shown in the paper by Bonow et al' comparing imaging using FDG with that using 20`T1 and by our clinical study6 comparing the kinetics of FDG with those of t2Rb in patients with evolving myocardial infarction. This equivalency makes sense because both intermediary metabolism and cell membrane integrity are necessary for cell viability.
However, the proviso must be that the measures are taken under the right conditions and with the right protocol. Myocardial FDG uptake is highly dependent on substrate availability and on conditions of fasting, glucose loading, catecholamine and hormone levels, and diabetes.6-'2 The accuracy of judging viability with FDG may therefore be variable, with viable myocardium failing to take up FDG under some conditions and necrotic myocardium taking up FDG under others.6,7"10-'2 In the study by Bonow et al,' the conditions were chosen appropriately for using FDG as a standard for viability. However, under the broad range of conditions seen in clinical practice, FDG imaging may be difficult to interpret as a measure of viability in up to 20% of patients who need myocardial viability studies,67"10 particularly in diabetics or in patients tested after fasting. These limitations of FDG are due to its uptake (or lack thereof) being affected by factors unrelated to viability or necrosis. The correlation between necrosis of myocardium and severely reduced myocardial uptake of a potassium analogue like 20MT1 or 82Rb is due to two processes: 1) low 201T1 delivery at low flows for more than a few hours, as in chronic coronary artery disease, is associated with necrotic myocardium or scar tissue; 2) even with adequate flow and radionuclide delivery after reperfusion, the radionuclide is not trapped or leaks out from necrotic tissue after initial uptake, leaving a "washout" defect on the 10-15 minute reinjection image. By either of these mechanisms, those myocardial areas with less than 50% of peak normal activity on the 20`TI reinjection image fail to take up FDG and are therefore necrotic, as defined by the absence of intermediary metabolism. Both of these mechanisms have been well defined for potassium experimentally,34 and for 82Rb experimentally5 and clinically, in comparison with FDG in patients with recent or old myocardial infarction. 6 The relative contribution of these two mechanisms (i.e., low flow/low tracer delivery and failure to retain 20`T1 [washout] ) to the final defect severity on the resting or reinjection image depends on whether reperfusion has occurred and on the acuteness of the infarction. For fixed myocardial scar tissue in chronic stable coronary heart disease, the defect severity is probably associated primarily with low flow/low tracer delivery, as observed by Bonow et al.1 For acutely infarcted, reperfused myocardium, in which flow and delivery of tracer may be normal, the washout phenomenon and failure to retain the delivered tracer is probably the primary cause of the defect, as demonstrated by clinical studies with 82Rb.6 PET Versus SPECT Technology There is a common misunderstanding about the technological advantages of PET over single photon emission computed tomography (SPECT) in determining severity of disease. The paper by Bonow et a1l demonstrates that with the correct protocol, 201T1 SPECT is qualitatively comparable to PET with cyclotron-produced FDG for imaging myocardial viability. The question is how can that be true given the better attenuation correction and technical imaging characteristics of PET?
Imaging myocardial necrosis involves high image contrasts between normal and abnormal areas, that is, detection of very low activity in one area as a small percent of the normal maximum activity. In its defense, such high contrast can be adequately imaged qualitatively by SPECT. However, the technical advantages of PET, particularly attenuation correction, become most apparent when quantitative size or quantitative intensity of defect severity must be measured and when lesser contrasts between normal and abnormal must be differentiated, as in detection and quantification of more graded differences in radionuclide distribution reflecting the spectrum of reduced flow reserve due to coronary artery stenosis over a range from mild to severe narrowing.14-18
The essential clinical question often is, when deciding on a definitive intervention, how much myocardium is viable? In our early experience, although 70-80% of postinfarction left ventricular regions may be viable by 20MT1 SPECT or PET, the total amount of viable myocardium adds up to a large enough size to warrant intervention in only 30% to 40% of patients. Therefore, sizing the myocardial infarction and/or viable areas as a percent of the zone of impaired flow reserve at risk becomes the real clinical issue that determines the value of a clinical methodology. The study by Bonow et all does not address this question.
However, their paper returns`01T1 imaging for determining of myocardial viability to the mainstream of our knowledge about the behavior of potassium and potassium analogues from the conceptual wilderness of 4-and 24-hour stress-redistribu-tion protocols. Although explanations or mechanisms are not proved, the paper by Bonow et a1l provides important empirical support for the concept of assessment of cell membrane integrity for a potassium analogue as a measure of myocardial viability or infarction, comparable to imaging intermediary metabolism using FDG.
